Comparison of Lewis-Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
03 2020
Historique:
received: 16 02 2019
accepted: 27 09 2019
pubmed: 2 10 2019
medline: 25 3 2021
entrez: 2 10 2019
Statut: ppublish

Résumé

Whether the Lewis-Sumner syndrome (L-SS) is a distinct entity from other types of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP-ot) remains controversial. The clinical/electrophysiological characteristics and long-term outcomes of 45 L-SS and 35 CIDP-ot patients were retrospectively compared. The CIDP-ot group was composed of 11 patients with a typical CIDP, 17 with a pure sensory form, four with a distal form and three with a pure motor form. In the L-SS group, asymmetric (P < 0.001) and monomelic involvement (P = 0.04) of the upper limbs (P < 0.001) was significantly more frequent; paucisymptomatic forms (Overall Neuropathy Limitations Scale ≤ 1) were less frequent (P < 0.001); electroneuromyography showed that conduction block in intermediate nerve segments was the main demyelinating feature, with frequent F-wave abnormalities on nerves without conduction block (44%). Long-term prognosis was globally poorer in the L-SS group with more frequent aggravation during treatment (P = 0.02), less frequent treatment withdrawal (P = 0.03) and longer time to achieve successful withdrawal (39 vs. 15 months). Our study suggests that L-SS patients have a less favourable therapeutic response rate and long-term outcomes. Rapid differentiation of L-SS from other forms of CIDP is important in order to anticipate a more complicated disease course management, with from one side the inefficacy or even harmfulness of corticosteroids and from the other side a difficult weaning procedure. A prospective study is necessary to confirm these results.

Sections du résumé

BACKGROUND AND PURPOSE
Whether the Lewis-Sumner syndrome (L-SS) is a distinct entity from other types of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP-ot) remains controversial.
METHOD
The clinical/electrophysiological characteristics and long-term outcomes of 45 L-SS and 35 CIDP-ot patients were retrospectively compared.
RESULTS
The CIDP-ot group was composed of 11 patients with a typical CIDP, 17 with a pure sensory form, four with a distal form and three with a pure motor form. In the L-SS group, asymmetric (P < 0.001) and monomelic involvement (P = 0.04) of the upper limbs (P < 0.001) was significantly more frequent; paucisymptomatic forms (Overall Neuropathy Limitations Scale ≤ 1) were less frequent (P < 0.001); electroneuromyography showed that conduction block in intermediate nerve segments was the main demyelinating feature, with frequent F-wave abnormalities on nerves without conduction block (44%). Long-term prognosis was globally poorer in the L-SS group with more frequent aggravation during treatment (P = 0.02), less frequent treatment withdrawal (P = 0.03) and longer time to achieve successful withdrawal (39 vs. 15 months).
CONCLUSIONS
Our study suggests that L-SS patients have a less favourable therapeutic response rate and long-term outcomes. Rapid differentiation of L-SS from other forms of CIDP is important in order to anticipate a more complicated disease course management, with from one side the inefficacy or even harmfulness of corticosteroids and from the other side a difficult weaning procedure. A prospective study is necessary to confirm these results.

Identifiants

pubmed: 31574194
doi: 10.1111/ene.14101
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

522-528

Informations de copyright

© 2019 European Academy of Neurology.

Références

Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15: 50-56.
Busby M, Donaghy M. Chronic dysimmune neuropathy: a subclassification based upon the clinical features of 102 patients. J Neurol 2003; 250: 714-724.
Kuwabara S, Isose S, Mori M, et al. Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2015; 86: 1054-1059.
Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32: 958-964.
Viala K, Renié L, Maisonobe T, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127: 2010-2017.
Attarian S, Verschueren A, Jérome F, Salort-Campana E, Jouve E, Pouget J. Response to treatment in patients with Lewis-Sumner syndrome. Muscle Nerve 2011; 44: 179-184.
Verschueren A, Azulay JP, Attarian S, Boucraut J, Pellissier JF, Pouget J. Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve 2005; 31: 88-94.
Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999; 22: 560-566.
Parry GJ. Are multifocal motor neuropathy and Lewis-Sumner syndrome distinct nosologic entities? Muscle Nerve 1999; 22: 557-559.
Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J Peripher Nerv Syst 1997; 2: 362-369.
Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology 2000; 54: 26-32.
Rajabally YA, Chavada G. Lewis-Sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve 2009; 39: 206-220.
Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. J Peripher Nerv Syst 2010; 15: 1-9.
Koutlidis RM, Ayrignac X, Pradat PF, et al. Segmental somatosensory-evoked potentials as a diagnostic tool in chronic inflammatory demyelinating polyneuropathies, and other sensory neuropathies. Clin Neurophysiol 2014; 44: 267-280.
Jongbloed BA, Bos JW, Rutgers D, van der Pol WL, van den Berg LH. Brachial plexus magnetic resonance imaging differentiates between inflammatory neuropathies and does not predict disease course. Brain Behav 2017; 7: e00632.
Shibuya K, Sugiyama A, Ito S, et al. Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2015; 77: 333-337.
Shimizu F, Sawai S, Sano Y, et al. Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. PLoS ONE 2014; 9: 1-9.
Kuwabara S, Misawa S. Chronic inflammatory demyelinating polyneuropathy: clinical subtypes and their correlation with electrophysiology. Clin Exp Neuroimmunol 2011; 2: 41-48.

Auteurs

G Fargeot (G)

CRMR Neuropathies Périphériques Rares, INSERM U1195, Hôpital Bicêtre, APHP, Le Kremlin Bicêtre, France.

T Maisonobe (T)

Département de Neurophysiologie Clinique, Hôpital Pitié Salpêtrière, APHP, Paris, France.

D Psimaras (D)

Département de Neurophysiologie Clinique, Hôpital Pitié Salpêtrière, APHP, Paris, France.

R Debs (R)

Département de Neurophysiologie Clinique, Hôpital Pitié Salpêtrière, APHP, Paris, France.

T Lenglet (T)

Département de Neurophysiologie Clinique, Hôpital Pitié Salpêtrière, APHP, Paris, France.

D Adams (D)

CRMR Neuropathies Périphériques Rares, INSERM U1195, Hôpital Bicêtre, APHP, Le Kremlin Bicêtre, France.

C Vandendries (C)

Service d'imagerie, Fondation Ophtalmologique Adolphe de Rothschild, APHP, Paris, France.

C Labeyrie (C)

CRMR Neuropathies Périphériques Rares, INSERM U1195, Hôpital Bicêtre, APHP, Le Kremlin Bicêtre, France.

K Viala (K)

Département de Neurophysiologie Clinique, Hôpital Pitié Salpêtrière, APHP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH